The development of mono- and bivalent degraders continues to gain traction, but biopharma faces challenges in rapidly discovering, validating, and utilizing novel E3 ligases. This leaves therapeutic opportunities untapped due to obstacles in ligase screening, structural characterization, and assaying therapeutic efficacy.

The Annual Ligase Targeting Drug Development Summit, now in its 4th year, will unite 80+ ligase experts dedicated to tackling ligase bottlenecks through data-driven presentations, technical discussions, and interactive sessions, unlocking the potential of E3 ligases for novel drug targets.

Event Link here.